HOME >> BIOLOGY >> NEWS
Liver transplant patients gain same benefits from CellCept as kidney transplant patients

25th May 2005, Basel, Switzerland New data reported in over 90 abstracts presented at the American Transplant Congress in Seattle show that liver transplant patients taking the immunosuppressant CellCept are gaining the same positive benefits already demonstrated in kidney transplant patients. This is good news for patients as the demand for liver transplants is increasing, with many of the cases directly resulting from chronic hepatitis C virus (HCV) infection.

Benefits seen with CellCept include:

  • Reduced risk of acute rejection, especially in patients infected with HCV
    • graft rejection is of particularly high risk in HCV patients and is associated with increased morbidity and decreased patient and graft survival (Abstract 928)

  • Safe and effective steroid-free regimens for HCV patients
    • steroids are known to have a negative impact on the progression of HCV, which can result in liver fibrosis (Abstract 475)

  • Optimal kidney function
    • CellCept taken with a low dose of tacrolimus showed a trend towards improved kidney function (Abstract 1240). CellCept is proven to promote excellent kidney function early after kidney transplantation in renal patients taking tacrolimus(1)

  • Less liver fibrosis
    • recipients taking CellCept-based regimens showed a significant reduction in the inflammation and structural changes that can lead to liver failure (Abstract 1446)

  • No increased risk of malignancy
    • the addition of CellCept to maintenance immunosuppression that includes tacrolimus and corticosteroids did not increase the risk of death due to malignant complications (Abstract 930). This confirms previous data as seen in kidney transplant recipients(2)

"It's really exciting to see liver transplant recipients benefiting from CellCept in the same way as kidney transplant patients.
'"/>

Contact: Vicky Singlehurst
vicky.singlehurst@ketchum.com
+44-207-611-3523
Ketchum
25-May-2005


Page: 1 2

Related biology news :

1. Liverpool amongst first in UK to install unique DNA sequencing technology
2. University of Liverpool launches 10 million small animal teaching hospital
3. Liverpool scientists work to improve water quality in Ghana
4. Liver regeneration may be simpler than previously thought
5. 2.5M boost for marine biology in Liverpool
6. Liver signal critical for insulins brain action
7. International scientists to present MRSA research in Liverpool
8. UC Davis, Lawrence Livermore researchers
9. Liver cancer linked to cellular repair pathway
10. Liver metabolism goes to pot
11. Liverpool vet creates pain relief diet for arthritic dogs

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/7/2016)... --  Veridium , a leader in biometrics-based authentication ... James Stickland . Stickland, a seasoned financial ... served in senior executive roles for HSBC, JPMorgan ... a pipeline of venture capital and accelerating innovation ... as managing director of U.K.-based fintech firm Red ...
(Date:12/6/2016)... Valencell , the leading innovator in ... a third consecutive year of triple digit growth for ... with a 360 percent increase in companies who have ... driven by sales of its wrist and ear Benchmark™ ... technology for hearables for fitness and healthcare applications. ...
(Date:12/5/2016)... , Dec. 5, 2016  The Office ... today published "Can CT Scans Enhance or Replace ... the potential of supporting or replacing forensic autopsies ... CT scan. In response to recommendations ... is exploring using CT scans as a potential ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... DES MOINES, Iowa , Dec. 8, 2016 Eurofins ... for US Food and President of Eurofins Scientific Inc. (ESI). ... Food Division with his proven professional and entrepreneurial experience in leading ... growth in the US food testing market to uphold Eurofins, status ... ...
(Date:12/8/2016)... , December 8, 2016 ... expanded its customisable SureSeq™ NGS panel range with the launch ... fast and cost-effective study of variants in familial hypercholesterolemia (FH). ... variation (CNV) detection on a single small panel and allows ... content. This includes all exons for LDLR , ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... World Technology Awards. uBiome is one of just six company finalists in the ... In addition to uBiome, companies nominated as finalists in this year’s awards include ...
(Date:12/8/2016)... Dec. 8, 2016  HedgePath Pharmaceuticals, Inc. (OTCQX: ... develops and plans to commercialize innovative therapeutics for ... common stock were approved for trading on the ... on the OTCQX, effective today, under the ticker ... OTCQX market, companies must meet high financial standards, ...
Breaking Biology Technology:
Cached News: